# Takeda Pharmaceutical Company Limited (TAK)

Source: https://www.quantisnow.com/company/TAK
Generated: 2026-11-14T02:44:25.032Z

- Ticker: TAK
- Exchange: NYSE
- Sector: Health Care
- Industry: Biotechnology: Pharmaceutical Preparations
- IPO year: 2018
- SEC CIK: 0001395064
- Website: takeda.com

## About

Takeda Pharmaceutical Company Limited engages in the research, development, manufacturing, and marketing of pharmaceutical products, over-the-counter medicines and quasi-drug consumer products, and other healthcare products. It offers pharmaceutical products in the areas of gastroenterology; oncology; neuroscience; and rare diseases, such as rare metabolic and hematology, and heredity angioedema, as well as plasma-derived therapies and vaccines. The company provides its products under the ENTYVIO, GATTEX/REVESTIVE, ALOFISEL, NATPARA, ADYNOVATE/ADYNOVI, TAKHZYRO, ELAPRASE, VPRIV, GAMMAGARD LIQUID/KIOVIG, HYQVIA, CUVITRU, ALBUMIN/FLEXBUMIN, NINLARO, and ALUNBRIG brands. It operates in Japan, the United States, Europe and Canada, Russia/CIS, Latin America, rest of Asia, the Middle East, Oceania, and Africa. The company has licensing agreements with Denali Therapeutics, and Wave Life Sciences Ltd; collaboration agreements with Neurocrine Biosciences, Inc, and Rani Therapeutics LLC; a license and research agreement with The University of Texas MD Anderson Cancer Center and Arrowhead Pharmaceuticals Inc.; a research collaboration agreements with Arrowhead Pharmaceuticals Inc. and Ovid Therapeutics Inc.; and a multi-target rare disease collaboration with Evox Therapeutics Ltd., as well as licensing agreement with ProThera Biologics Inc. It also has a strategic alliance with Egle Therapeutics SAS and Evotec SE; a strategic partnership with Neurocrine Biosciences, Inc.; Carmine Therapeutics and HemoShear Therapeutics, LLC; strategic collaboration with KSQ Therapeutics to research, develop, and commercialize immune-based therapies for cancer; and strategic collaboration with Anima Biotech. Takeda Pharmaceutical Company Limited was founded in 1781 and is headquartered in Tokyo, Japan.

## Latest TAK news and filings

- 2026-11-12 12:35 UTC [Takeda Launches ORZEYFUL™ (oveporexton), the First and Only Medicine of Its Kind for Narcolepsy Type 1 Now Available in the United States](https://www.quantisnow.com/insight/takeda-launches-orzeyful-oveporexton-the-first-and-only-medicine-of-6786283)
- 2026-11-05 20:54 UTC [SEC Form 4] [President, IBU Platford Giles Richard sold $1,162,395 worth of American Depositary Shares (55,617 units at $20.90), decreasing direct ownership by 17% to 270,253 units (SEC Form 4)](https://www.quantisnow.com/insight/president-ibu-platford-giles-richard-sold-1162395-worth-of-american-6775844)
- 2026-11-04 22:35 UTC [SEC Form 4] [President, OBU Bitetti Teresa Marie sold $973,662 worth of American Depositary Shares (46,609 units at $20.89), decreasing direct ownership by 18% to 214,501 units (SEC Form 4)](https://www.quantisnow.com/insight/president-obu-bitetti-teresa-marie-sold-973662-worth-of-american-6773657)
- 2026-10-29 10:49 UTC [SEC Form 6-K] [SEC Form 6-K filed by Takeda Pharmaceutical Company Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-takeda-pharmaceutical-company-limited-6762277)
- 2026-10-29 10:33 UTC [SEC Form 6-K] [SEC Form 6-K filed by Takeda Pharmaceutical Company Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-takeda-pharmaceutical-company-limited-6762217)
- 2026-10-29 06:36 UTC [Earnings Date] [Takeda Announces FY2026 First-Half Results Highlighting Launch Momentum and Pipeline Milestones](https://www.quantisnow.com/insight/takeda-announces-fy2026-first-half-results-highlighting-launch-momentum-and-pipeline-6761976)
- 2026-10-23 11:30 UTC [Takeda Announces Arcotatug Tavatecan (TAK-921) Demonstrated Statistically Significant and Clinically Meaningful Improvements in Overall Survival and Progression-Free Survival in Phase 3 Advanced Gastric Cancer Study](https://www.quantisnow.com/insight/takeda-announces-arcotatug-tavatecan-tak-921-demonstrated-statistically-significant-and-clinically-6755817)
- 2026-10-19 09:30 UTC [First and Only Ulcerative Colitis Treat-to-Target Trial Shows Treating to Disease Clearance vs. Symptomatic Remission with ENTYVIO® (vedolizumab) Prolongs Time to First Disease-Related Complication](https://www.quantisnow.com/insight/first-and-only-ulcerative-colitis-treat-to-target-trial-shows-treating-to-6749748)
- 2026-10-15 00:30 UTC [Takeda’s ORZEYFUL (oveporexton) Launches Simultaneously in Japan and China Giving Physicians First Access to Prescribe Novel Orexin Agonist to Patients with Narcolepsy Type 1](https://www.quantisnow.com/insight/takedas-orzeyful-oveporexton-launches-simultaneously-in-japan-and-china-giving-6747029)
- 2026-09-30 05:00 UTC [Zasocitinib Delivered Superior Efficacy Versus Deucravacitinib in New Phase 3 Head-to-Head Results, Reinforcing Potential to Deliver Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill](https://www.quantisnow.com/insight/zasocitinib-delivered-superior-efficacy-versus-deucravacitinib-in-new-phase-3-6729715)
- 2026-09-16 01:12 UTC [SEC Form 4] [Chief Transformation Officer Duprey Lauren Rusckowski sold $640,279 worth of American Depositary Shares (34,535 units at $18.54), decreasing direct ownership by 15% to 191,522 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-transformation-officer-duprey-lauren-rusckowski-sold-640279-worth-of-6716714)
- 2026-09-14 10:25 UTC [SEC Form 6-K] [SEC Form 6-K filed by Takeda Pharmaceutical Company Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-takeda-pharmaceutical-company-limited-6713592)
- 2026-09-14 07:00 UTC [U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis, with Potential to Redefine Oral Treatment Expectations](https://www.quantisnow.com/insight/us-fda-accepts-new-drug-application-under-priority-review-for-6713507)
- 2026-09-09 12:24 UTC [New England Journal of Medicine Publishes Data from Phase 3 Studies Demonstrating Oveporexton (ORZEYFUL) Improved the Full Range of Narcolepsy Type 1 Symptoms and Quality of Life](https://www.quantisnow.com/insight/new-england-journal-of-medicine-publishes-data-from-phase-3-6709390)
- 2026-09-04 01:49 UTC [SEC Form 4] [President, R&D Plump Andrew Stewart sold $2,148,372 worth of American Depositary Shares (116,191 units at $18.49) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/president-rd-plump-andrew-stewart-sold-2148372-worth-of-american-6706059)
- 2026-08-29 01:10 UTC [SEC Form 6-K] [SEC Form 6-K filed by Takeda Pharmaceutical Company Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-takeda-pharmaceutical-company-limited-6698944)
- 2026-08-28 22:40 UTC [Takeda Receives U.S. FDA Approval of MIMRYLO™ (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera](https://www.quantisnow.com/insight/takeda-receives-us-fda-approval-of-mimrylo-rusfertide-marking-a-6698780)
- 2026-08-24 06:36 UTC [ORZEYFUL (oveporexton) Approved in Japan as the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1](https://www.quantisnow.com/insight/orzeyful-oveporexton-approved-in-japan-as-the-first-and-only-6691931)
- 2026-08-21 20:30 UTC [SEC Form 4] [President, R&D Plump Andrew Stewart sold $363,347 worth of American Depositary Shares (19,651 units at $18.49) as part of a pre-agreed trading plan (SEC Form 4)](https://www.quantisnow.com/insight/president-rd-plump-andrew-stewart-sold-363347-worth-of-american-6691485)
- 2026-08-19 20:15 UTC [SEC Form 4] [Chief Human Resources Officer Greenway Nicola Deidre Petal sold $235,118 worth of American Depositary Shares (12,980 units at $18.11), decreasing direct ownership by 24% to 40,049 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-human-resources-officer-greenway-nicola-deidre-petal-sold-235118-6688416)
- 2026-08-13 01:54 UTC [SEC Form 4] [Chief Medical Officer Farajallah Awny Samaan Botros sold $239,503 worth of American Depositary Shares (14,006 units at $17.10), decreasing direct ownership by 11% to 116,177 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-medical-officer-farajallah-awny-samaan-botros-sold-239503-worth-6678917)
- 2026-08-13 01:53 UTC [SEC Form 4] [President, PDT BU Ibrahim Ramy Riad Ahmed sold $124,437 worth of American Depositary Shares (7,277 units at $17.10), decreasing direct ownership by 7% to 102,588 units (SEC Form 4)](https://www.quantisnow.com/insight/president-pdt-bu-ibrahim-ramy-riad-ahmed-sold-124437-worth-6678916)
- 2026-08-13 01:53 UTC [SEC Form 4] [President, U.S. Business Unit Pacheco Rhonda Janice sold $289,007 worth of American Depositary Shares (16,901 units at $17.10), decreasing direct ownership by 8% to 182,507 units (SEC Form 4)](https://www.quantisnow.com/insight/president-us-business-unit-pacheco-rhonda-janice-sold-289007-worth-6678915)
- 2026-08-13 01:51 UTC [SEC Form 4] [Chief Transformation Officer Duprey Lauren Rusckowski sold $813,721 worth of American Depositary Shares (47,586 units at $17.10), decreasing direct ownership by 17% to 226,057 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-transformation-officer-duprey-lauren-rusckowski-sold-813721-worth-of-6678914)
- 2026-08-13 01:50 UTC [SEC Form 4] [President, R&D Plump Andrew Stewart sold $2,828,220 worth of American Depositary Shares (165,393 units at $17.10), decreasing direct ownership by 18% to 766,569 units (SEC Form 4)](https://www.quantisnow.com/insight/president-rd-plump-andrew-stewart-sold-2828220-worth-of-american-6678913)
- 2026-08-13 01:46 UTC [SEC Form 4] [Head, Strat. & Port. Dev Pignagnoli Agosti Marcello sold $392,565 worth of American Depositary Shares (22,957 units at $17.10), decreasing direct ownership by 11% to 176,977 units (SEC Form 4)](https://www.quantisnow.com/insight/head-strat-port-dev-pignagnoli-agosti-marcello-sold-392565-worth-6678911)
- 2026-08-13 01:45 UTC [SEC Form 4] [President, OBU Bitetti Teresa Marie sold $855,205 worth of American Depositary Shares (50,012 units at $17.10), decreasing direct ownership by 17% to 252,010 units (SEC Form 4)](https://www.quantisnow.com/insight/president-obu-bitetti-teresa-marie-sold-855205-worth-of-american-6678910)
- 2026-08-13 01:42 UTC [SEC Form 4] [Pres., Global Supply & Quality Shannon Elaine Mary sold $68,024 worth of American Depositary Shares (3,978 units at $17.10), decreasing direct ownership by 6% to 63,333 units (SEC Form 4)](https://www.quantisnow.com/insight/pres-global-supply-quality-shannon-elaine-mary-sold-68024-worth-6678906)
- 2026-08-13 01:39 UTC [SEC Form 4] [Chief Data & Tech. Officer Ricci Gabriele sold $429,005 worth of American Depositary Shares (25,088 units at $17.10), decreasing direct ownership by 13% to 171,654 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-data-tech-officer-ricci-gabriele-sold-429005-worth-of-6678903)
- 2026-08-13 01:28 UTC [SEC Form 4] [Chief Human Resources Officer Greenway Nicola Deidre Petal sold $115,835 worth of American Depositary Shares (6,774 units at $17.10), decreasing direct ownership by 11% to 53,029 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-human-resources-officer-greenway-nicola-deidre-petal-sold-115835-6678892)
- 2026-08-13 01:27 UTC [SEC Form 4] [President and CEO Kim Julie So-Young sold $1,523,439 worth of American Depositary Shares (89,090 units at $17.10), decreasing direct ownership by 19% to 391,489 units (SEC Form 4)](https://www.quantisnow.com/insight/president-and-ceo-kim-julie-so-young-sold-1523439-worth-of-6678891)
- 2026-08-13 01:25 UTC [SEC Form 4] [President, IBU Platford Giles Richard sold $531,519 worth of American Depositary Shares (31,083 units at $17.10), decreasing direct ownership by 9% to 315,838 units (SEC Form 4)](https://www.quantisnow.com/insight/president-ibu-platford-giles-richard-sold-531519-worth-of-american-6678890)
- 2026-08-13 01:23 UTC [SEC Form 4] [Global General Counsel Furney Natalie Anne Marie sold $527,843 worth of American Depositary Shares (30,868 units at $17.10), decreasing direct ownership by 13% to 204,298 units (SEC Form 4)](https://www.quantisnow.com/insight/global-general-counsel-furney-natalie-anne-marie-sold-527843-worth-6678888)
- 2026-08-12 20:10 UTC [SEC Form 4] [Chief Human Resources Officer Greenway Nicola Deidre Petal sold $605,778 worth of American Depositary Shares (34,603 units at $17.51), decreasing direct ownership by 37% to 59,803 units (SEC Form 4)](https://www.quantisnow.com/insight/chief-human-resources-officer-greenway-nicola-deidre-petal-sold-605778-6677924)
- 2026-08-12 20:10 UTC [SEC Form 4] [Pres., Global Supply & Quality Shannon Elaine Mary sold $357,371 worth of American Depositary Shares (20,363 units at $17.55), decreasing direct ownership by 23% to 67,311 units (SEC Form 4)](https://www.quantisnow.com/insight/pres-global-supply-quality-shannon-elaine-mary-sold-357371-worth-6677918)
- 2026-08-06 01:37 UTC [SEC Form 6-K] [SEC Form 6-K filed by Takeda Pharmaceutical Company Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-takeda-pharmaceutical-company-limited-6666805)
- 2026-08-05 22:10 UTC [U.S. FDA Approves Takeda’s ORZEYFUL™ (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1](https://www.quantisnow.com/insight/us-fda-approves-takedas-orzeyful-oveporexton-the-first-and-only-6666541)
- 2026-07-30 10:01 UTC [SEC Form 6-K] [SEC Form 6-K filed by Takeda Pharmaceutical Company Limited](https://www.quantisnow.com/insight/sec-form-6-k-filed-by-takeda-pharmaceutical-company-limited-6654638)
- 2026-07-30 06:37 UTC [Earnings Date] [Takeda Announces FY2026 First Quarter Results, Near-Term Launch Preparations and Pipeline Progress on Track](https://www.quantisnow.com/insight/takeda-announces-fy2026-first-quarter-results-near-term-launch-preparations-and-6654538)
- 2026-07-16 22:00 UTC [Takeda’s Zasocitinib Demonstrates Consistent, High Rates of Skin Clearance Across the Body, Including Hard-to-Treat and High-Impact Sites, in Phase 3 Psoriasis Studies](https://www.quantisnow.com/insight/takedas-zasocitinib-demonstrates-consistent-high-rates-of-skin-clearance-across-6640232)

## More

- Live page with ratings, short volume, options and peers: https://www.quantisnow.com/company/TAK
- Earnings history: https://www.quantisnow.com/earnings/TAK
- Dividend history: https://www.quantisnow.com/dividends/TAK
- Insider transactions: https://www.quantisnow.com/insiders/TAK
- Options chain: https://www.quantisnow.com/options/TAK
- SEC 8-K filings only: https://www.quantisnow.com/company/TAK/8-k
- RSS and alerts for TAK: https://www.quantisnow.com/docs/rss-feeds.md